Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | NEK2 | P51955 | 1/20 | 0.32 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29406125 | 1.00 | MAPT (0.37) | MAPTALDH1A1L3MBTL1NSD2EGFR | |
| SCHEMBL2523285 | 0.89 | TDP1 (0.34) | MAPTALDH1A1L3MBTL1NSD2EGFR | |
| SCHEMBL6733419 | 0.84 | MAPT (0.38) | MAPTALDH1A1L3MBTL1NSD2EGFR | |
| SCHEMBL31310908 | 0.84 | MAPT (0.38) | MAPTALDH1A1L3MBTL1NSD2EGFR | |
| SCHEMBL29492107 | 0.84 | ALDH1A1 (0.30) | ALDH1A1L3MBTL1RAB9A | |
| SCHEMBL333685 | 0.84 | ALDH1A1 (0.30) | ALDH1A1L3MBTL1RAB9A | |
| SCHEMBL2512861 | 0.83 | HTR6 (0.32) | HTR6 | |
| Fluoride Ion SCHEMBL29695344 | 0.81 | MAPT (0.35) | MAPTALDH1A1L3MBTL1NSD2EGFR | |
| SCHEMBL15421207 | 0.81 | — | — | |
| SCHEMBL19713586 | 0.78 | MAPT (0.33) | MAPTALDH1A1L3MBTL1NSD2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 957 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577236-B2 | Processes for preparation of Tezacaftor | LAURUS LABS LIMITED (IN) | 2026-03-17 | — | — | US | claimed |
| EP-2427468-B2 | PREPARATION OF A METAL COMPLEX | JOHNSON MATTHEY PLC (GB) | 2025-06-04 | — | — | EP | claimed |
| US-12233402-B2 | Cross-coupling reaction catalysts, and methods of making and using same | YALE UNIVERSITY (US) | 2025-02-25 | — | — | US | claimed |
| US-20250002519-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | UNIV YALE (US) | 2025-01-02 | — | — | US | claimed |
| US-20240300922-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-09-12 | — | — | US | claimed |
| US-12071445-B2 | Precatalyst scaffolds for cross-coupling reactions, and methods of making and using same | YALE UNIVERSITY (US) | 2024-08-27 | — | — | US | claimed |
| US-20240279399-A1 | POLYMERS FOR USE IN ELECTRONIC DEVICES | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2024-08-22 | — | — | US | claimed |
| EP-4359401-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | Blueprint Medicines Corporation (US) | 2024-05-01 | — | — | EP | claimed |
| EP-4352134-A1 | POLYMERS FOR USE IN ELECTRONIC DEVICES | DuPont Electronics, Inc. (US) | 2024-04-17 | — | — | EP | claimed |
| CN-117881670-A | Methods of making EGFR inhibitors | 缆图药品公司 | 2024-04-12 | — | — | CN | claimed |
| EP-1931618-B1 | PROCESS FOR THE PRODUCTION OF ANILINES | SYNGENTA PARTICIPATIONS AG (CH) | 2009-08-05 | — | — | EP | claimed |
| US-7531695-B2 | Therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICAL, INC (US) | 2009-05-12 | — | — | US | claimed |
| EP-1931618-A1 | PROCESS FOR THE PRODUCTION OF ANILINES | Syngeta Participations AG (CH) | 2008-06-18 | — | — | EP | claimed |
| US-20070129392-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS, INC. | 2007-06-07 | — | — | US | claimed |
| US-20070078189-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | AUSPEX PHARMACEUTICALS (US) | 2007-04-05 | — | — | US | claimed |
| WO-2007025693-A1 | PROCESS FOR THE PRODUCTION OF ANILINES | SYNGENTA PARTICIPATIONS AG (CH) | 2007-03-08 | — | — | WO | claimed |
| EP-1636160-A4 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2006-09-27 | — | — | EP | claimed |
| EP-1636160-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | Auspex Pharmaceuticals (US) | 2006-03-22 | — | — | EP | claimed |
| WO-2005108338-A1 | NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-11-17 | — | — | WO | claimed |
| WO-2005000233-A2 | NOVEL THERAPEAUTIC AGENTS FOR THE TREATMENT OF CANCER, METABOLIC DISEASES AND SKIN DISORDERS | AUSPEX PHARMACEUTICALS (US) | 2005-01-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250002519-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | TIMCC, YAP1, TET2 | MAPT 3401/4885ALDH1A1 1759/4885L3MBTL1 3951/4885 |
| US-12577236-B2 | Processes for preparation of Tezacaftor | CYP4A11, F9, CYP3A4 | MAPT 3497/4885ALDH1A1 189/4885L3MBTL1 3644/4885 |
| US-20240300922-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | MAPT 2551/4885ALDH1A1 2197/4885L3MBTL1 4875/4885 |
| US-20070078189-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | GPR119, IGF1R, CCNE2 | MAPT 4729/4885ALDH1A1 463/4885L3MBTL1 2056/4885 |
| US-20070129392-A1 | Novel therapeutic agents for the treatment of cancer, metabolic diseases and skin disorders | IGF1R, INSR, BRCA1 | MAPT 4558/4885ALDH1A1 826/4885L3MBTL1 579/4885 |
| US-12233402-B2 | Cross-coupling reaction catalysts, and methods of making and using same | TET2, TIMCC, MDM4 | MAPT 3755/4885ALDH1A1 1625/4885L3MBTL1 4560/4885 |
| US-12071445-B2 | Precatalyst scaffolds for cross-coupling reactions, and methods of making and using same | TIMCC, YAP1, TET2 | MAPT 3084/4885ALDH1A1 2091/4885L3MBTL1 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.